Dose escalation of ripretinib can lead to response in advanced gastrointestinal stromal tumor patients refractory to the standard dose: a report of two cases

Authors :: Muhammad O. Hakim
Jonathan C. Trent
Ramon O. Minjares
Emily Jonczak
Andrea P. Espejo-Freire
Ty K. Subhawong
Brianna Nicole Valdes
Navin Chakravarthy Balaji
Alan S. Livingstone
Caroline Hana
Gina Z. D'Amato
Anthony Frank Skryd
Priscila Barreto-Coelho
Philippos Apolinario Costa
Source :: Gastrointestinal Stromal Tumor. 4:1-1
Publication Year :: 2021
Publisher :: AME Publishing Company, 2021.

Subjects :: Oncology
medicine.medical_specialty
Refractory
business.industry
Internal medicine
medicine
Dose escalation
Stromal tumor
business
Lead (electronics)

Full Text Access

Tools